News 04.10.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will introduce proof-of-concept data for its new CD3 Switch-DARPin designed to...
Events, Internal events 04.10.2024 Personal Branding is too often overlooked as many think of it as “selling” themselves. It’s rather a self discovery journey that allows you to better understand your strengths and how you can leverage them to have win-win career conversations that will see you thrive, perform better and achieve your goals...
Events, Internal events
Event date: 26.05.2025
Join the Life Science Zurich Impact Conference at Technopark Zurich on May 26, 2025, and connect with leading experts from academia, industry, and investment.
Top speakers and exciting sessions await you: LSZ Impact Program 2025
Register now and be part of the future: https://lsz-impact2025.b2match.io/
News 27.09.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present on its lead-212 (212Pb)-labeled Radio-DARPin Therapeutic (RDT) targeting delta-like...
News 25.09.2024 Boehringer Ingelheim said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets. With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&D) pipeline, specifically in the fast-growing pet therapeutics category. As life expectancy for...